PCM
KDNY

Palisade Capital Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Palisade Capital Management’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-10,096
Closed -$571K – 584
2016
Q2 		$571K Buy
10,096
+619
+7% +$37.6K 0.02% 457
2016
Q1 		$607K Sell
9,477
-213
-2% -$17.2K 0.02% 454
2015
Q4 		$1.36M Sell
9,690
-152
-2% -$20.6K 0.04% 386
2015
Q3 		$953K Sell
9,842
-2,996
-23% -$357K 0.03% 417
2015
Q2 		$1.95M Buy
+12,838
New +$2.12M 0.05% 365

Other funds holding KDNY

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Palisade Capital Management's KDNY Position: Q3 2016 in Review

Palisade Capital Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2016, closing a stake of 10,096 shares — an estimated $571K sold.

Palisade Capital Management first reported a position in KDNY in Q2 2015 and held it in 5 quarters. The position peaked at $1.95M in Q2 2015. 92 funds tracked by Wall St. Rank hold KDNY as of Q3 2016.

  • Palisade Capital Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2016 after selling out during the quarter.
  • Palisade Capital Management sold 10,096 Chinook Therapeutics, Inc. Common Stock shares in Q3 2016, an estimated $571K.
  • Palisade Capital Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 5 quarters.
  • Palisade Capital Management's Chinook Therapeutics, Inc. Common Stock position peaked at $1.95M in Q2 2015.
  • 92 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2016.

Based on Palisade Capital Management's 13F filing for Q3 2016, filed 8 Nov 2016.